{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:10Z","timestamp":1740108310913,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00228-022-03324-z","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T06:03:24Z","timestamp":1651644204000},"page":"1087-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4906-3910","authenticated-orcid":false,"given":"Jeanne","family":"Allard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pauline","family":"Gagaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"3324_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1060028020941852","volume":"55","author":"C Chung","year":"2021","unstructured":"Chung C (2021) New therapeutic targets and treatment options for thrombotic microangiopathy: caplacizumab and ravulizumab. Ann Pharmacother 55:330\u2013343. https:\/\/doi.org\/10.1177\/1060028020941852","journal-title":"Ann Pharmacother"},{"key":"3324_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.mcna.2016.09.010","volume":"101","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Taylor JA (2017) Syndromes of thrombotic microangiopathy. Med Clin North Am 101:395\u2013415. https:\/\/doi.org\/10.1016\/j.mcna.2016.09.010","journal-title":"Med Clin North Am"},{"key":"3324_CR3","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.nephro.2017.01.016","volume":"13","author":"S Grang\u00e9","year":"2017","unstructured":"Grang\u00e9 S, Coppo P (2017) Thrombotic microangiopathies and antineoplastic agents. N\u00e9phrologie Th\u00e9rapeutique 13:S109\u2013S113. https:\/\/doi.org\/10.1016\/j.nephro.2017.01.016","journal-title":"N\u00e9phrologie Th\u00e9rapeutique"},{"key":"3324_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.13808","volume":"85","author":"F Daviet","year":"2019","unstructured":"Daviet F, Rouby F, Poullin P, Moussi-Franc\u00e8s J, Sall\u00e9e M, Burtey S et al (2019) Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol 85:403\u2013412. https:\/\/doi.org\/10.1111\/bcp.13808","journal-title":"Br J Clin Pharmacol"},{"key":"3324_CR5","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/cncr.20290","volume":"100","author":"BD Humphreys","year":"2004","unstructured":"Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG et al (2004) Gemcitabine-associated thrombotic microangiopathy. Cancer 100:2664\u20132670. https:\/\/doi.org\/10.1002\/cncr.20290","journal-title":"Cancer"},{"key":"3324_CR6","doi-asserted-by":"publisher","unstructured":"Burns ST, Damon L, Akagi N, Laszik Z, Ko AH (2020) Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature. Antican Res 40:3995\u20134000. https:\/\/doi.org\/10.21873\/anticanres.14393","DOI":"10.21873\/anticanres.14393"},{"key":"3324_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol CJASN 13:300\u2013317. https:\/\/doi.org\/10.2215\/CJN.00620117","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"3324_CR8","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","volume":"21","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O et al (2006) Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 21:3038\u20133045. https:\/\/doi.org\/10.1093\/ndt\/gfl507","journal-title":"Nephrol Dial Transplant"},{"key":"3324_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3123-6","volume":"79","author":"GE Ritchie","year":"2017","unstructured":"Ritchie GE, Fernando M, Goldstein D (2017) Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. Cancer Chemother Pharmacol 79:1\u20137. https:\/\/doi.org\/10.1007\/s00280-016-3123-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"3324_CR10","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit (n.d) http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0233843.htm.\u00a0Acccessed 7 Mar\u00a02022"},{"key":"3324_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027","journal-title":"JAMA"},{"key":"3324_CR12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395\u20132406. https:\/\/doi.org\/10.1056\/NEJMoa1809775","journal-title":"N Engl J Med"},{"key":"3324_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"3324_CR14","unstructured":"abraxane-epar-product-information_en.pdf (n.d)"},{"key":"3324_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1200\/JCO.18.00089","volume":"37","author":"T Macarulla","year":"2019","unstructured":"Macarulla T, Pazo-Cid R, Guill\u00e9n-Ponce C, L\u00f3pez R, Vera R, Reboredo M et al (2019) Phase I\/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol Off J Am Soc Clin Oncol 37:230\u2013238. https:\/\/doi.org\/10.1200\/JCO.18.00089","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3324_CR16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13031","volume":"13","author":"KN MacDougall","year":"2021","unstructured":"MacDougall KN, Schwartz B, Harewood J, Bukhari Z, Neculiseanu E (2021) A case of gemcitabine-induced thrombotic microangiopathy treated with ravulizumab in a patient with stage IV pancreatic cancer. Cureus 13:e13031. https:\/\/doi.org\/10.7759\/cureus.13031","journal-title":"Cureus"},{"key":"3324_CR17","doi-asserted-by":"publisher","unstructured":"Kashima H, Minami R, Ozawa T, Matsumoto A, Kimura Y, Takeda Y et al (2022) A case of thrombotic microangiopathy during chemotherapy with gemcitabine in a patient with pancreatic cancer. Nihon Shokakibyo Gakkai Zasshi Jpn J Gastro-Enterol 119:259\u2013266. https:\/\/doi.org\/10.11405\/nisshoshi.119.259","DOI":"10.11405\/nisshoshi.119.259"},{"issue":"Suppl 1","key":"3324_CR18","first-page":"3s","volume":"82","author":"P Alberto","year":"1995","unstructured":"Alberto P (1995) Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity. Bull Cancer (Paris) 82(Suppl 1):3s\u20138s","journal-title":"Bull Cancer (Paris)"},{"key":"3324_CR19","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2017):155"},{"key":"3324_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245. https:\/\/doi.org\/10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"3324_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2125.1982.tb01361.x","volume":"13","author":"U Busto","year":"1982","unstructured":"Busto U, Naranjo CA, Sellers EM (1982) Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol 13:223\u2013227. https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb01361.x","journal-title":"Br J Clin Pharmacol"},{"key":"3324_CR22","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit (n.d)\u00a0http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0240468.htm. Accessed 23 Mar\u00a02022"},{"key":"3324_CR23","doi-asserted-by":"publisher","unstructured":"Gr\u00fcndlingh J (2014) Martindale: The complete drug reference 38th edition. J Forensic Leg Med 28:54. https:\/\/doi.org\/10.1016\/j.jflm.2014.10.001","DOI":"10.1016\/j.jflm.2014.10.001"},{"key":"3324_CR24","unstructured":"Meyler\u2019s Side Effects of Drugs | ScienceDirect (n.d.)\u00a0https:\/\/www.sciencedirect.com\/referencework\/9780444537164\/meylers-side-effects-of-drugs. Accessed 17 July\u00a02021"},{"key":"3324_CR25","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/(sici)1097-0142(19990501)85:9<2023::aid-cncr21>3.0.co;2-2","volume":"85","author":"MC Fung","year":"1999","unstructured":"Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023\u20132032. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990501)85:9%3c2023::aid-cncr21%3e3.0.co;2-2","journal-title":"Cancer"},{"key":"3324_CR26","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","volume":"21","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O et al (2006) Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 21:3038\u20133045. https:\/\/doi.org\/10.1093\/ndt\/gfl507","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"3324_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00280-002-0560-1","volume":"51","author":"SS Shord","year":"2003","unstructured":"Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA et al (2003) Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51:328\u2013336. https:\/\/doi.org\/10.1007\/s00280-002-0560-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"3324_CR28","doi-asserted-by":"publisher","unstructured":"Willemsen AE, van Herpen CM, Wesseling P, Bult P, van Laarhoven HW (2011)\u00a0Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. Acta Oncol 50:462\u2013465. https:\/\/doi.org\/10.3109\/0284186X.2010.491088","DOI":"10.3109\/0284186X.2010.491088"},{"key":"3324_CR29","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jamaoncol.2018.3277","volume":"4","author":"V Sahai","year":"2018","unstructured":"Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS et al (2018) Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma. JAMA Oncol 4:1707\u20131712. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3277","journal-title":"JAMA Oncol"},{"key":"3324_CR30","doi-asserted-by":"publisher","unstructured":"Martin K, Roberts V, Chong G, Goodman D, Hill P, Ierino F (2019) Eculizumab therapy in gemcitabine-induced thrombotic microangiopathy in a renal transplant recipient. Oxf Med Case Rep\u00a02019:omz048. https:\/\/doi.org\/10.1093\/omcr\/omz048","DOI":"10.1093\/omcr\/omz048"},{"key":"3324_CR31","unstructured":"FDA Highlights of Prescribing Information (n.d) Gemcitabine"},{"key":"3324_CR32","unstructured":"Quantitative Prediction of Drug Interactions (n.d) DDI-Predictor Academic version.\u00a0https:\/\/www.ddi-predictor.org\/. Accessed 17 July\u00a02021"},{"key":"3324_CR33","unstructured":"Drugs.com Prescription drug information interactions & side effects\u00a0(n.d) DrugsCom.\u00a0https:\/\/www.drugs.com\/. Accessed 17 July\u00a02021"},{"key":"3324_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/diagnostics12020286","volume":"12","author":"A Comandatore","year":"2022","unstructured":"Comandatore A, Immordino B, Balsano R, Capula M, Garajov\u00e0 I, Ciccolini J et al (2022) Potential role of exosomes in the chemoresistance to gemcitabine and nab-paclitaxel in pancreatic cancer. Diagn Basel Switz 12:286. https:\/\/doi.org\/10.3390\/diagnostics12020286","journal-title":"Diagn Basel Switz"},{"key":"3324_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","volume":"2","author":"KK Frese","year":"2012","unstructured":"Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI et al (2012) nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2:260\u2013269. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0242","journal-title":"Cancer Discov"},{"key":"3324_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/FPC.0000000000000086","volume":"24","author":"ML Alvarellos","year":"2014","unstructured":"Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ et al (2014) PharmGKB summary: gemcitabine pathway. Pharmacogenet Genomics 24:564\u2013574. https:\/\/doi.org\/10.1097\/FPC.0000000000000086","journal-title":"Pharmacogenet Genomics"},{"key":"3324_CR37","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3\u201310","journal-title":"Semin Oncol"},{"key":"3324_CR38","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1158\/1078-0432.CCR-05-1969","volume":"12","author":"JA Gilbert","year":"2006","unstructured":"Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED et al (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12:1794\u20131803. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1969","journal-title":"Clin Cancer Res"},{"key":"3324_CR39","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17:v7-12. https:\/\/doi.org\/10.1093\/annonc\/mdj941","journal-title":"Ann Oncol"},{"key":"3324_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/FPC.0b013e32825ea6e3","volume":"17","author":"C Mercier","year":"2007","unstructured":"Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C et al (2007) Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 17:841\u2013844. https:\/\/doi.org\/10.1097\/FPC.0b013e32825ea6e3","journal-title":"Pharmacogenet Genomics"},{"key":"3324_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim S-R, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al (2007) Pharmacokinetics of gemcitabine in japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32\u201342. https:\/\/doi.org\/10.1200\/JCO.2006.06.7405","journal-title":"J Clin Oncol"},{"key":"3324_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/15257770802145447","volume":"27","author":"E Giovannetti","year":"2008","unstructured":"Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S et al (2008) Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27:720\u2013725. https:\/\/doi.org\/10.1080\/15257770802145447","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"3324_CR43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41397-020-00203-7","volume":"21","author":"C Vivaldi","year":"2021","unstructured":"Vivaldi C, Crucitta S, Catanese S, Cucchiara F, Arrigoni E, Pecora I et al (2021) Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Pharmacogenomics J 21:233\u2013242. https:\/\/doi.org\/10.1038\/s41397-020-00203-7","journal-title":"Pharmacogenomics J"},{"key":"3324_CR44","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.5301\/jbm.5000076","volume":"29","author":"H Li","year":"2014","unstructured":"Li H, Wang X, Wang X (2014) The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis. Int J Biol Markers 29:e224-232. https:\/\/doi.org\/10.5301\/jbm.5000076","journal-title":"Int J Biol Markers"},{"key":"3324_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gene.2015.01.010","volume":"559","author":"X Ding","year":"2015","unstructured":"Ding X, Chen W, Fan H, Zhu B (2015) Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 559:31\u201337. https:\/\/doi.org\/10.1016\/j.gene.2015.01.010","journal-title":"Gene"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03324-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T09:15:33Z","timestamp":1654766133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03324-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3324"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03324-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}